Table 1.

Summary of most relevant studies specifically reporting on the relapse rates after discontinuation of anti-TNF therapy in adult populations with Crohn's disease, following a variable period of therapy (Note: only studies with >30 patients were included).

Author, year (study type)	No. of patients	Definition of remission	% on concomitant IM	Relapse rate at 12 months	Relapse rate 24 months	Outcome at last follow-up
Molnar, 2008 (Retrospective)	50 (treated with IND therapy only)	Clinical remission	86%	56%	–	–
Waugh, 2010 (Retrospective)	48	Steroid-free clinical remission	67%	–	–	65% relapsed (median follow-up of 4.1 Y)
Louis, 2012 (Prospective)	115	Steroid-free clinical remission	100%	43.9 ± 5%	52.2 ± 2%	–
Molnar, 2013 (prospective)	121	Clinical remission	85%	45%		–
Papamichael, 2014 (Retrospective)	100 (65% treated episodically)	Clinical remission	84%	4%	7%	48% relapsed (median follow-up 9.7 Y)
Chauvin, 2014 (Prospective)	92 (54 treated w/IND only and 38 w/MAINT therapy)	Clinical remission	100%	IND: 22% MAINT: 44%	IND: 40% MAINT: 64%	IND: 74% (median follow-up: 4.6 Y) MAINT: 68% (median follow-up: 3.2 Y)
Monterubbianesi, 2015 (Retrospective)	58	Clinical remission	66%	31%	52%	–
Armuzzi, 2010 (Retrospective)	43	Clinical remission	NS	–	–	49% relapsed (median follow-up 1.1 Y)
Steenholdt, 2012	53	Clinical remission	87%	39%	50% (23 months)	68% (median follow-up 1.5 Y)
Dai, 2014 (Prospective)	109	Clinical remission	41%	21%	–	–
Kennedy, 2015 (Retrospective)	146	Clinical remission	65%	36%	56%	51% (median follow-up of 2 Y)
Brooks, 2014 (Prospective)	86	Clinical and/or endoscopic remission	80%	36%	–	–
Echarri, 2013 (Retrospective)	32	Steroid-free clinical remission, endoscopic and radiological remission	93%	22%	47%	–
Rismo, 2014 (Prospective)	37	Endoscopic remission	84%	74%	–	–
Bortlik, 2015 (Prospective)	61	Clinical and endoscopic remission	77%	41%	49%	52.6% (median follow-up 2.5 Y)

Y, years; IND, induction; MAINT, maintenance; NS, non-specified.